This difference in the anti-tumor effects of IFN-inducible chemokines was suggested to be dependent on the sensitivity to DPP4/CD26 [46,47], an enzyme that cleaves chemokines expressed in tumor tissues. Here, DPP4 is linked to neoplasm.